Mechanistic Insight into the Suppression of Polyglutamine Aggregation by SRCP1
ACS Chemical Biology · 2023
DOI: 10.1021/acschembio.2c00893 ↗At a glance
Journal article in ACS Chemical Biology, 2023. Written by Holly N Haver and 5 co-authors. Institution: Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina 27710, United States. Major MEDLINE topics: Protein Aggregates, Dictyostelium. Cited 5 times so far (Crossref); 65 references. The full text is freely available in PubMed Central. Funded by: NINDS NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.
Abstract (original language)
Protein aggregation is a hallmark of the polyglutamine diseases. One potential treatment for these diseases is suppression of polyglutamine aggregation. Previous work identified the cellular slime mold Dictyostelium discoideum as being naturally resistant to polyglutamine aggregation. Further work identified serine-rich chaperone protein 1 (SRCP1) as a protein that is both necessary in Dictyostelium and sufficient in human cells to suppress polyglutamine aggregation. Therefore, understanding how SRCP1 suppresses aggregation may be useful for developing therapeutics for the polyglutamine diseases. Here we utilized a de novo protein modeling approach to generate predictions of SRCP1's structure. Using our best-fit model, we generated mutants that were predicted to alter the stability of SRCP1 and tested these mutants' stability in cells. Using these data, we identified top models of SRCP1's structure that are consistent with the C-terminal region of SRCP1 forming a β-hairpin with a highly dynamic N-terminal region. We next generated a series of peptides that mimic the predicted β-hairpin and validated that they inhibit aggregation of a polyglutamine-expanded mutant huntingtin exon 1 fragment in vitro. To further assess mechanistic details of how SRCP1 inhibits polyglutamine aggregation, we utilized biochemical assays to determine that SRCP1 inhibits secondary nucleation in a manner dependent upon the regions flanking the polyglutamine tract. Finally, to determine if SRCP1 more could generally suppress protein aggregation, we confirmed that it was sufficient to inhibit aggregation of polyglutamine-expanded ataxin-3. Together these studies provide details into the structural and mechanistic basis of the inhibition of protein aggregation by SRCP1.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina 27710, United States.
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
- Department of Neurology, Duke University, Durham, North Carolina 27710, United States.
- Duke Center for Neurodegeneration and Neurotherapeutics, Durham, North Carolina 27710, United States.
ORCID profiles: Brian F Volkman, K Matthew Scaglione
Funding
- NINDS NIH HHS
- NIGMS NIH HHS
- NIAID NIH HHS
- NIH HHS
- National Institute of Neurological Disorders and Stroke
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Office of the Director
- National Institute of General Medical Sciences
Cite
APA
Haver, H. N., Wedemeyer, M., Butcher, E., Peterson, F. C., Volkman, B. F., & Scaglione, K. M. (2023). Mechanistic Insight into the Suppression of Polyglutamine Aggregation by SRCP1. ACS Chemical Biology. https://doi.org/10.1021/acschembio.2c00893
Vancouver
Haver HN, Wedemeyer M, Butcher E, Peterson FC, Volkman BF, Scaglione KM. Mechanistic Insight into the Suppression of Polyglutamine Aggregation by SRCP1. ACS Chemical Biology. 2023. doi:10.1021/acschembio.2c00893
BibTeX
@article{Haver2023,
author = {Haver, Holly N and Wedemeyer, Michael and Butcher, Erin and Peterson, Francis C and Volkman, Brian F and Scaglione, K Matthew},
title = {Mechanistic Insight into the Suppression of Polyglutamine Aggregation by SRCP1},
journal = {ACS Chemical Biology},
year = {2023},
doi = {10.1021/acschembio.2c00893}
}
EUVIMED